Jafron Biomedical Co.,Ltd. (SHE:300529)
China · Delayed Price · Currency is CNY 19.52
+0.07 (0.36%)
May 15, 2026, 9:45 AM CST
Jafron Biomedical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 564.55 | 532.82 | 820.2 | 436.49 | 889.56 | 1,197 |
Depreciation & Amortization | 119.67 | 119.67 | 127.2 | 94.79 | 73.99 | 54.06 |
Other Amortization | 16.58 | 16.58 | 16.95 | 18.19 | 8.63 | 4.68 |
Loss (Gain) From Sale of Assets | 0.08 | 0.08 | -3.64 | -6.72 | -0.86 | -0.98 |
Asset Writedown & Restructuring Costs | 53.59 | 53.59 | 6.24 | 27.07 | 7.86 | 1.15 |
Loss (Gain) From Sale of Investments | -53.49 | -53.49 | -43.11 | - | -10.51 | -28.72 |
Provision & Write-off of Bad Debts | - | - | - | - | -1.99 | 6.76 |
Other Operating Activities | 19.36 | 64.26 | 63.35 | 45 | 27.72 | 7.69 |
Change in Accounts Receivable | 10.65 | 10.65 | -8.22 | 277.22 | -7.9 | -110.41 |
Change in Inventory | 38.62 | 38.62 | 41.56 | -37.3 | -152.74 | -75.93 |
Change in Accounts Payable | -58.16 | -58.16 | 0.45 | 52.14 | 60.66 | 203.27 |
Change in Other Net Operating Assets | 3.64 | 3.64 | 35.49 | 10.87 | -8.59 | 8.27 |
Operating Cash Flow | 708.05 | 721.22 | 1,051 | 916.74 | 883.8 | 1,249 |
Operating Cash Flow Growth | -12.90% | -31.38% | 14.64% | 3.73% | -29.26% | 30.49% |
Capital Expenditures | -162.7 | -172.59 | -235.14 | -247.25 | -475.89 | -537.41 |
Sale of Property, Plant & Equipment | 1.42 | 2.86 | 5.34 | 12.6 | 6.91 | 0.99 |
Cash Acquisitions | - | - | - | - | -0.18 | - |
Investment in Securities | 139.46 | 812.88 | -908.45 | -15 | 163.26 | -133.8 |
Other Investing Activities | -0.49 | - | 10.78 | - | - | - |
Investing Cash Flow | -22.33 | 643.15 | -1,127 | -249.65 | -305.9 | -670.22 |
Short-Term Debt Issued | - | - | 1 | - | - | - |
Long-Term Debt Issued | - | 100.27 | 325.08 | 762.92 | 296.32 | 998.3 |
Total Debt Issued | 96.07 | 100.27 | 326.08 | 762.92 | 296.32 | 998.3 |
Short-Term Debt Repaid | - | -1 | - | - | - | - |
Long-Term Debt Repaid | - | -265.74 | -654.5 | -349.47 | -6.11 | -6.02 |
Total Debt Repaid | -252.45 | -266.74 | -654.5 | -349.47 | -6.11 | -6.02 |
Net Debt Issued (Repaid) | -156.39 | -166.46 | -328.43 | 413.45 | 290.21 | 992.28 |
Issuance of Common Stock | 232.76 | 232.76 | 14.22 | 123.81 | 67.29 | 195.09 |
Repurchase of Common Stock | - | - | -371.28 | -382.58 | -5.19 | -500.13 |
Common Dividends Paid | -643.25 | -643.57 | -340.12 | -561.79 | -729.42 | -531.02 |
Other Financing Activities | -95.97 | 13.94 | 35.78 | -44.8 | 11.19 | 8.94 |
Financing Cash Flow | -662.85 | -563.33 | -989.82 | -451.91 | -365.93 | 165.18 |
Foreign Exchange Rate Adjustments | -3.69 | -1.72 | 0.43 | 0.01 | -0.04 | -0 |
Net Cash Flow | 19.19 | 799.32 | -1,066 | 215.19 | 211.93 | 744.37 |
Free Cash Flow | 545.35 | 548.63 | 815.85 | 669.49 | 407.91 | 712 |
Free Cash Flow Growth | -12.22% | -32.75% | 21.86% | 64.13% | -42.71% | 18.59% |
Free Cash Flow Margin | 26.94% | 27.27% | 30.47% | 34.83% | 16.37% | 26.61% |
Free Cash Flow Per Share | 0.71 | 0.71 | 1.04 | 0.84 | 0.51 | 0.89 |
Cash Income Tax Paid | 425.97 | 400.62 | 468.12 | 255.53 | 441.93 | 427.62 |
Levered Free Cash Flow | 280.48 | 383.66 | 508.63 | 535.7 | 18.61 | 228.28 |
Unlevered Free Cash Flow | 312.74 | 417.11 | 548.45 | 569.66 | 41.13 | 233.85 |
Change in Working Capital | -12.3 | -12.3 | 63.81 | 301.92 | -110.6 | 7.96 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.